Financial Data and Key Metrics Changes - As of December 31, 2025, the company reported cash equivalents and investments of $258.3 million, with an additional $23.7 million received from a favorable arbitration outcome [13][14] - The net loss for Q4 2025 was $38.8 million, or $0.17 per share, while the full year net loss was $189.9 million, or $0.87 per share [16][17] - Research and development expenses for Q4 2025 were $28.6 million, totaling $150.2 million for the full year [15][17] Business Line Data and Key Metrics Changes - The focus for 2026 is on delivering clinical milestones for cema-cel in ALPHA3 and ALLO-329 in RESOLUTION, with significant emphasis on the allogeneic CAR T platform [4][6] - ALPHA3 aims to redefine management of large B-cell lymphoma by testing early intervention with cema-cel [5][8] - ALLO-329 is designed for autoimmune diseases, targeting CD19 and CD70, with proof of concept data expected in June 2026 [6][10] Market Data and Key Metrics Changes - The company has over 60 active clinical sites across the U.S. and Canada, with plans to expand to Australia and South Korea [9] - The integration of cema-cel into community cancer centers is seen as a core advantage, expanding access to advanced cell therapy [9] Company Strategy and Development Direction - The company aims to validate its allogeneic platform as a scalable and accessible solution for cell therapy [4][6] - There is a strategic focus on prioritizing resources for programs with the greatest potential for demonstrating the advantages of allogeneic CAR T [6][12] - The company is positioned for long-term value creation with a cash runway extended into the first quarter of 2028 [15][17] Management's Comments on Operating Environment and Future Outlook - Management believes that the cell therapy landscape is shifting towards evidence-based practices, emphasizing data and disciplined execution [4] - The upcoming year is viewed as critical for generating proof points that could validate the allogeneic platform [4][6] - Management expressed confidence in the ability to execute through important inflection points with a focus on high-impact programs [17][18] Other Important Information - The company has made prudent use of its ATM equity facility, raising an additional $20.7 million year to date [14] - Guidance for operating cash expenses in 2026 is expected to be approximately $150 million, with GAAP operating expenses around $210 million [17] Q&A Session Summary Question: Safety parameters for ALPHA3 data update - Management plans to provide high-level safety information, focusing on serious adverse events and outpatient delivery feasibility [20][21] Question: Insights from ZUMA-7 MRD analysis - Management views the ZUMA-7 study as consistent with their expectations for MRD clearance and its correlation to clinical outcomes [23][24] Question: Interim analysis and MRD conversion - Management indicated that while MRD clearance may correlate with clinical outcomes, the relationship is not fully established [28][29] Question: Expectations for ALLO-329 data - The target product profile for ALLO-329 includes low or no lymphodepletion, with ongoing studies testing these parameters [31][32] Question: Market opportunity and stem cell positioning - Management is monitoring the evolving landscape of large B-cell lymphoma treatments and believes MRD positivity rates will remain largely unchanged [34][36] Question: Enrollment pace for ALPHA3 study - Enrollment is on track to be completed by the end of 2027, with MRD positivity rates consistent with expectations [67][68]

Financial Data and Key Metrics Changes - Net sales for Q4 2025 increased by 13.7% to $115.6 million from $101.6 million in Q4 2024, driven by $8.2 million in volume growth and a $6.3 million favorable impact from pricing and product mix [8][12] - Gross profit for Q4 2025 was $39.3 million, compared to $39.8 million in the prior year quarter, with a gross margin of 34.0%, down from 39.2% [10][12] - Net income for Q4 2025 rose by 22.8% to $7.2 million, with a net income margin of 6.2%, up from 5.8% in the prior year quarter [12] Business Line Data and Key Metrics Changes - Sales to chain accounts and distributors, the largest sales channel, increased by 17.5% in Q4 2025, while online sales rose by 1.9% and retail channel sales declined by 4.8% [8] - The new paper bag product category is gaining momentum, contributing to revenue growth and expanding market share [5][6] - Eco-friendly product sales grew to 37.3% of total revenue in Q4 2025, up from 34.5% in Q4 2024 [6] Market Data and Key Metrics Changes - The import mix during Q4 2025 consisted of 46% from Taiwan, 14% from China, 13% from the United States, and 11% each from Vietnam and Malaysia [4] - The California market is experiencing a slowdown, with overall restaurant closures impacting competition, although the company has seen double-digit growth due to tariff containment [48] Company Strategy and Development Direction - The company is focused on diversifying sourcing and optimizing margins, with expectations of margin improvements beginning in Q2 2026 due to favorable tariff developments [5][16] - Continued expansion in the paper bag category and the addition of new customer accounts are key strategies for driving top-line growth [17] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing trade volatility but emphasized the company's ability to deliver profitable growth [4] - For Q1 2026, the company expects net sales to increase by approximately 8%-10%, with gross margin anticipated to be within 34%-36% [16] - Management is optimistic about achieving low double-digit growth for the full year 2026, driven by market share gains and new product offerings [20][26] Other Important Information - The company generated operating cash flow of $15.4 million and free cash flow of $14.6 million in Q4 2025, despite high duties and tariff payments [13] - A regular quarterly dividend of $0.45 per share was approved, with $12.0 million remaining available for share repurchase [14][15] Q&A Session Summary Question: Outlook for 2026 and market assumptions - Management anticipates low double-digit growth, primarily from market share gains in new product categories, despite a competitive environment [20] Question: Q1 revenue slowdown and weather impact - Weather-related shutdowns in Texas and the East Coast affected Q1 performance, but trends are improving as conditions stabilize [22] Question: Full year revenue guidance and business opportunities - Revenue guidance includes potential new accounts in the final confirmation stages, but management remains conservative due to testing phases [26] Question: Margin outlook and energy costs - Energy costs are accounted for in margin guidance, with expectations of a 10%-15% year-over-year increase in ocean freight shipping costs [36] Question: Online sales growth and future platforms - Management expects double-digit growth in online sales for 2026, driven by the addition of new platforms and bulk sales strategies [40] Question: Demand for eco-friendly products and California market conditions - Demand for eco-friendly products remains strong, particularly for molded fiber and paper bags, while the California market is competitive with some restaurant closures [48]

Financial Data and Key Metrics Changes - The company reported approximately $690,000 in revenue from continuing operations for fiscal year 2025, entirely generated from the TrueCut Motion platform and related motion grading services [14] - The cash balance at the end of 2025 was approximately $11.2 million, which increased to approximately $62 million after the sale of the Shanghai subsidiary [4][15] - The company expects cash operating expenses to be approximately $2 million per quarter starting in the second quarter of 2026 [17] Business Line Data and Key Metrics Changes - The sale of the Shanghai semiconductor subsidiary allowed the company to reposition itself as a global technology licensing business focused on cinematic visualization solutions [5][6] - The company has transformed into a lean, asset-light organization with less than 25 full-time employees, 60% of whom are dedicated to R&D [7] Market Data and Key Metrics Changes - The company is focusing on expanding its TrueCut Motion platform, which is being utilized by leading filmmakers for premium theatrical releases [8][10] - There is a growing number of premium large format (PLF) screens, with major exhibitors investing in expanding premium theatrical experiences, which aligns with the company's strategy [9] Company Strategy and Development Direction - The company aims to enhance its core strengths in visualization enhancement solutions and pursue new licensing initiatives [6] - The immediate strategic focus is on enabling additional premium large format theatrical experiences and increasing demand for TrueCut Motion grading services [11] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of maintaining a robust balance sheet and managing resources prudently to build a profitable licensing business [12] - The company is optimistic about the market opportunity for its motion grading technology and expertise, particularly in the premium theatrical segment [10] Other Important Information - The company has approximately $1.2 million in escrow related to a tax dispute that is expected to be resolved in its favor [5] - The company has no intention of selling more patents and is focused on adding to its patent portfolio specific to its go-forward business [35] Q&A Session Summary Question: What are the best near-term opportunities for revenue? - Management highlighted the focus on engaging with studios and distributors to deliver premium experiences and the potential for revenue from home entertainment devices [20][24] Question: What is the margin structure as revenue forms? - Management indicated that gross margins are expected to be very high across various revenue streams, including content creation and licensing [26] Question: What are the top priorities for 2026? - The primary priorities include licensing the TrueCut Motion technology to third parties and developing demand for the product [37]

Financial Data and Key Metrics Changes - In Q4 2025, EverCommerce reported revenue of $151.2 million, reflecting a 5.2% year-over-year growth [5][18] - Adjusted EBITDA for the quarter was $44.2 million, with a margin of 29.2%, indicating operational efficiency [6][18] - Pro forma revenue for the last twelve months was $591.7 million, representing a 6.4% year-over-year growth [7][18] - Adjusted gross profit was $117 million, resulting in an adjusted gross margin of 77.5% [18] - Cash flow from operations for the year was $111.5 million, slightly down from $113.2 million in the previous year [21] Business Line Data and Key Metrics Changes - EverHealth and EverPro verticals were highlighted as key areas of focus, with significant improvements in product strategy and customer experience [4][5] - The company repurchased 2.5 million shares for $24.8 million during the quarter, demonstrating a commitment to shareholder return [5][6] - Multi-solution customers grew by 26% year-over-year, with 286,000 customers enabled for more than one solution [14] Market Data and Key Metrics Changes - The annualized total payments volume (TPV) expanded to $13 billion, indicating strong market performance [7] - The top six solutions saw TPV grow by 17.4% year-over-year, contributing significantly to overall revenue growth [15][40] Company Strategy and Development Direction - The company is focusing on embedding AI into its platforms to enhance customer workflows and operational efficiency [9][11] - Investments in AI-driven features are expected to drive growth and improve customer retention [10][25] - The strategy includes enabling payments at the point of initial SaaS sale and driving cross-sell into the existing customer base [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for 2026, driven by AI investments and operational improvements [24][34] - The company anticipates continued revenue growth in the second and third quarters, aligning with typical seasonal performance [24][56] - Management emphasized the importance of AI as a value creation driver for customers, enhancing their operational capabilities [9][10] Other Important Information - The company completed the sale of its Marketing Technology Solutions business, which was seen as a positive move for growth predictability [3][5] - Leadership updates included the appointment of Matt Feierstein as CEO of EverPro, expected to enhance execution and growth [16] Q&A Session Summary Question: Customer appetite for AI solutions - Management noted strong uptake in AI functionalities across EverPro and EverHealth, with positive early metrics from ZyraTalk [27][29] Question: 2026 growth outlook assumptions - The company expects growth driven by AI investments and improved customer engagement, with a focus on re-acceleration throughout the year [33][34] Question: Payments revenue decline explanation - The decline in non-top six payment solutions was not significantly related to the MarTech divestiture, with focus on mature and growth parts of the portfolio [38][40] Question: Competitive advantages in the AI landscape - Management highlighted data advantages from customer interactions and deep vertical expertise as key competitive moats [41][42] Question: Incremental revenue from no-show prediction tool - The no-show prediction tool is included in packages, with expectations for overall ASP increases as new features are added [48]

Financial Data and Key Metrics Changes - For Q4, net sales were $273 million, up 9% compared to Q3, exceeding expectations [26] - Gross margin was at 41%, slightly higher than guidance, maintaining above 40% for seven of the last eight quarters [26] - SG&A expenses decreased by 12% year-over-year to $91 million [26] - Adjusted EBITDA for Q4 was $23 million, at the high end of expectations [26] Business Line Data and Key Metrics Changes - Funko core product lines are expected to grow high single digits year-over-year in 2026, while Loungefly is projected to decline by double digits due to SKU cuts [28][29] - The Bitty Pop! product line has shown strong growth, contributing positively to sales [31] Market Data and Key Metrics Changes - In the EU, sales increased by 20% from January 2025 to January 2026, outperforming market growth [22] - The company is the second largest collectible brand by market share in Europe, following Pokémon [22] Company Strategy and Development Direction - The "Make Culture Pop!" strategy focuses on participating in cultural moments and expanding into new markets, particularly in Asia and Latin America [10][24] - A new Chief International Officer has been appointed to drive growth in Asia and Latin America, targeting significant opportunities in these regions [24] - The company aims to leverage its relationships with licensors and creators to tap into emerging cultural trends, especially from Asia [25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing a strong entertainment slate and growth in collectibles, licensed IP, and the kidult market as key drivers [32][33] - The company expects net sales to be flat to up 3% in 2026, with a substantial improvement in profitability anticipated [28][30] Other Important Information - The company has renewed licenses with major studios, ensuring a strong position for the upcoming film slate [45] - The introduction of a new program called HyperStrike aims to enhance speed in product development and capitalize on viral trends [16][20] Q&A Session Summary Question: Describe the shape of the flat to +3% guidance past Q1 - The guidance is expected to be consistent throughout the year, with Q2 anticipated to show growth over last year [34] Question: To what extent does Funko view original content creation as a growth driver? - Original content creation is seen as a long-term growth driver, with plans to partner with major studios for development [35] Question: Does Funko need to use any of its extended credit agreement in 2026? - The company does not expect to need additional borrowing and plans to manage operations on cash flows [38] Question: Can you break out the POS trends and inventory restocking domestically versus Europe? - Double-digit growth in POS sales was observed in Europe, while the US saw improving trends throughout Q4 [39] Question: What would you highlight as the key initiatives to drive top line results and margin versus 2025? - Key initiatives include leveraging the content slate, expanding international growth, and launching new products [40]

Financial Data and Key Metrics Changes - Total net revenues for Q1 FY2026 were $18.2 million, down from $34.3 million in Q1 FY2025, reflecting a strategic transition to Sunkist and exiting brokerage operations [15][16] - Agribusiness revenues decreased to $16.8 million from $32.9 million year-over-year [15] - Adjusted net loss was $8.5 million or $0.48 per diluted share, compared to an adjusted net loss of $2.5 million or $0.14 per diluted share in the prior year [20][21] - Operating loss for Q1 FY2026 was $10.6 million, compared to a loss of $5.3 million in the prior year [19] Business Line Data and Key Metrics Changes - Fresh packed lemon sales were $11.9 million, down from $21.2 million in the same period last year, with a decrease in volume sold from 1,147,000 cartons to 681,000 cartons [16][17] - No avocado revenue was recorded in Q1 FY2026, compared to $162,000 in the prior year due to harvest timing [17] - Orange revenue fell to $10,000 from $1.6 million, reflecting the sale of Chilean agricultural properties [17] Market Data and Key Metrics Changes - The average price for lemons in Q1 FY2026 was $17.41 per carton, down from $18.44 in the prior year, with prices softening to around $16 in February [40][42] - Avocado pricing is under pressure due to a large crop from Mexico, with current prices around $1.00 per pound for size 48 avocados [40] Company Strategy and Development Direction - The company is focused on a strategic transformation to create sustainable long-term value, including a partnership with Sunkist to enhance customer access and reduce pricing pressure [5][7] - Cost structure improvements are expected to generate $10 million in selling, general, and administrative savings for FY2026 [23] - Expansion of avocado production is underway, with 1,600 acres planted and an expected near 100% increase in production capacity over the next 2-4 years [8] Management's Comments on Operating Environment and Future Outlook - Management anticipates sequential improvement in financial results throughout FY2026, with the second quarter expected to show better performance than the first [11][24] - The company is optimistic about the avocado crop due to favorable weather conditions, which are expected to support strong growth in FY2027 [33][34] - The strategic initiatives are believed to position the company for improved profitability as revenue cadence normalizes in the second half of the year [23][24] Other Important Information - The company is advancing the monetization of non-strategic assets and water rights, with a focus on maximizing value from its water resources [10][48] - The real estate development project, Harvest at Limoneira, is expected to generate $155 million in proceeds over the next five fiscal years [9] Q&A Session Summary Question: On the $10 million in expected SG&A savings, how much will be visible in the first half versus the back half? - Management indicated that the savings will not be linear and will show more significant reductions in the latter half of the year [29][30] Question: Update on avocado weather conditions? - Management reported ideal weather conditions in California, with good rain and temperatures expected to accelerate fruit growth [33][34] Question: Impact of fruit pricing and weather on lemons? - Management noted that lemon pricing has softened due to market supply but expects it to improve as the season progresses [42][43] Question: Opportunities for monetization of water assets? - Management highlighted ongoing negotiations regarding Colorado River water rights and the potential for monetization in the near term [48][49]

Financial Data and Key Metrics Changes - INOVIO reported a net income of $3.8 million for Q4 2025, translating to $0.06 per share, while the total net loss for the full year was $84.9 million or $1.81 per share [25][26] - Total operating expenses decreased from $20.5 million in Q4 2024 to $17.5 million in Q4 2025, and full-year operational expenses dropped 23% from $112.6 million in 2024 to $86.9 million in 2025 [25][26] - Cash equivalents and short-term investments at the end of Q4 2025 were $58.5 million, down from $94.1 million as of December 31, 2024 [25] Business Line Data and Key Metrics Changes - The primary focus remains on advancing INO-3107 towards FDA approval, with significant resources allocated to this lead candidate [5][24] - INOVIO is also advancing other promising candidates in its pipeline, including INO-5412 for glioblastoma, through partnerships [8][22] Market Data and Key Metrics Changes - The market for recurrent respiratory papillomatosis (RRP) treatment is characterized by a significant burden on patients, with surgery being the standard of care [15] - Market research indicates that INO-3107 has the potential to become the preferred treatment option based on its efficacy and tolerability [16][18] Company Strategy and Development Direction - INOVIO's strategy includes optimizing resources to extend cash runway towards the October 30, 2026 PDUFA date for INO-3107 [24][60] - The company is leveraging partnerships to advance its pipeline and is focused on innovative treatments for rare diseases with significant unmet needs [22][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in INO-3107's ability to meet an unmet medical need and provide a meaningful therapeutic benefit over existing treatments [5][11] - The company is preparing for a meeting with the FDA to discuss the Accelerated Approval Program and has submitted additional documentation to support its case [10][30] Other Important Information - INOVIO has reduced its workforce by approximately 15% to conserve financial resources [24] - The company is actively preparing for the commercial launch of INO-3107, including selecting key commercial partners and finalizing its go-to-market model [19][24] Q&A Session Summary Question: What additional data is needed for the FDA regarding Accelerated Approval? - Management indicated that no new clinical data is required, but they have submitted an Assessment Aid to reiterate their rationale for Accelerated Approval [29][30] Question: How would a six-month priority review timeline impact launch preparations? - Management stated that they are focused on ensuring alignment with the FDA for Accelerated Approval and are well advanced in commercial preparations [33][34] Question: How are third-party logistics and commercial partners being used to inform distribution strategy? - Management noted that they are learning from competitors and leveraging the experience of their partners to ensure a well-prepared launch [42][43] Question: Can you explain the rationale behind the Akeso partnership for GBM? - Management explained that combining PD-1 and CTLA-4 blockade is expected to enhance immune responses against tumor-associated antigens [48][49] Question: What are the plans for moving forward with 3112 if INO-3107 is approved? - Management indicated that resources are currently focused on INO-3107, but if approved, they will consider advancing 3112 based on available financial resources [55]

Financial Data and Key Metrics Changes - In 2025, Nephros achieved a total revenue of $18.8 million, representing a 33% increase from $14.2 million in 2024 [9][10] - The net income for 2025 was approximately $1.2 million, compared to $0.1 million in 2024, marking the second consecutive year of profitability [13][14] - The gross margin for the fourth quarter of 2025 was 58%, down from 64% in the fourth quarter of 2024, primarily due to tariff impacts [11][12] Business Line Data and Key Metrics Changes - Active customer sites grew to over 1,680 by the end of 2025, up from just over 1,500 at the end of 2024 [10] - Programmatic sales accounted for over 90% of total revenues for both the fourth quarter and the full year [21][22] - Emergency response business showed high single-digit growth, contributing to overall revenue increases [21][24] Market Data and Key Metrics Changes - The company is expanding into non-patient care applications, targeting markets such as hospitality and commercial sectors [4][5] - Increased awareness of waterborne pathogens and rising regulatory expectations are driving demand for Nephros' solutions [9][10] Company Strategy and Development Direction - Nephros' strategy is built around three core pillars: products, services, and education, aimed at establishing the company as a leader in water safety solutions [5][8] - The company is focusing on expanding its market reach beyond traditional healthcare applications, leveraging education to inform potential customers about the importance of water safety [27][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's positioning amid increasing regulatory expectations and the need for reliable filtration solutions [9][10] - The company anticipates that growth in non-healthcare markets will take time, similar to the growth experienced in the hospital market [31][32] Other Important Information - Nephros remains debt-free with approximately $5.4 million in cash at year-end [10][15] - The company has launched the Nephros Water Institute to enhance knowledge around waterborne pathogen mitigation and compliance-driven filtration solutions [8] Q&A Session Summary Question: What percentage of revenues for the fourth quarter and the full year were programmatic sales? - Programmatic sales accounted for over 90% of the business for both the fourth quarter and the full year [21][22] Question: Can you discuss the pipeline potential outside of medical in the commercial space? - Management highlighted the importance of education in penetrating new markets and overcoming barriers to adoption [26][27] Question: Can you elaborate on some of the successes in newer markets? - Successes have been noted in correctional facilities, schools, and aviation facilities, where large populations are at risk [37][40]

Financial Data and Key Metrics Changes - Total revenue for the quarter was $16.6 million, a decrease of approximately 3% compared to $17 million in the prior year period [11] - Core study revenue reached a record $16.6 million, representing growth of approximately 32% from $12.6 million in the year-ago period [11] - Adjusted EBITDA for the quarter was $575,000, marking the third consecutive quarter of positive adjusted EBITDA [13] - GAAP loss from operations for the quarter was approximately $275,000 [13] - Gross margin for the quarter was 47%, down from 61% in the prior year period [13] Business Line Data and Key Metrics Changes - The core translational oncology services platform demonstrated strong performance, with record services revenue driven by effective study execution and conversion of previously booked work [3][11] - Data revenue was not recognized in the third quarter, compared to $4.5 million in the prior year period, contributing to the overall year-over-year revenue decline [12] - The company anticipates that data revenue will become a more meaningful contributor over time as the platform develops [12] Market Data and Key Metrics Changes - The company noted that customer budgets are stabilizing, leading to improved bookings converting into revenue [3] - There is a healthy underlying demand for the company's services, with expectations for revenue normalization as studies progress [4] Company Strategy and Development Direction - The company is focused on balancing growth and investment while maintaining positive adjusted EBITDA [5] - Investments are being made in both the data platform and the therapeutic subsidiary, Corellia, without diluting shares [5][9] - The company aims to maximize shareholder value across its differentiated tumor bank, radiopharmaceutical capabilities, and therapeutic subsidiary [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year revenue growth and positive adjusted EBITDA while continuing to invest in growth drivers [5][10] - The company expects to see the payoff from current investments beginning in fiscal 2027, with more meaningful acceleration anticipated in fiscal 2028 [5][10] - Discussions regarding external funding for Corellia are ongoing, with positive feedback from potential partners [8][9] Other Important Information - The company ended the quarter with $7.1 million in cash and no debt, maintaining a cash balance within projected ranges [16] - Operating expenses increased to $7.2 million, reflecting strategic investments in R&D, sales, and marketing [15] Q&A Session Summary - There were no questions from participants during the Q&A session [17]

Financial Data and Key Metrics Changes - For Q4 2025, total revenues were $2.2 million, a 76% increase from $1.3 million in Q4 2024, primarily due to higher unit sales of M400 smart glasses and increased engineering services sales [20] - For the full year 2025, total revenues reached $6.3 million, up 9% from $5.8 million in 2024, with product sales increasing by 4% year-over-year [21] - The overall gross loss for 2025 was $1.1 million, significantly improved from a loss of $5.6 million in 2024, mainly due to lower inventory obsolescence reserves [21] - The net loss attributable to common shareholders for Q4 2025 was $8.7 million or $0.12 per share, compared to a net loss of $13.7 million or $0.16 per share in Q4 2024 [25] - For the full year 2025, the net loss was $32.3 million or $0.42 per share, down from $73.5 million or $1.08 per share in 2024, with a notable impairment loss recorded in 2024 [26] Business Line Data and Key Metrics Changes - Engineering services sales for 2025 were $1.6 million, an increase of 27% from $1.3 million in 2024, reflecting growth in this segment [21] - Research and development expenses rose 31% to $12.6 million in 2025, driven by increased costs related to the new LX1 smart glasses and waveguide products [22] - Sales and marketing costs decreased by 33% to $5.5 million in 2025, primarily due to reductions in bad debt expense and headcount [23] Market Data and Key Metrics Changes - The enterprise markets are becoming more mature and ROI-driven, with customers focusing on solutions that improve workflow efficiency and enhance safety [17] - The defense and security agencies segment is seeing growth in active programs and discussions, with production orders starting to come in [12] Company Strategy and Development Direction - The company is focusing on its OEM products and waveguide technology as key growth engines, aiming to capitalize on opportunities in enterprise, defense, and consumer markets [7][8] - Vuzix plans to be more selective in investing in branded products, with future product activity driven by OEM customer demand [9] - The company aims to strengthen its position in the waveguide market, which is seen as a significant long-term opportunity [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth of the OEM business and waveguide technology, expecting revenues from these segments to surpass those from branded enterprise products by the end of 2026 [33] - The company anticipates multiple new business partnerships and orders throughout 2026, indicating a positive outlook for revenue growth [35] Other Important Information - Vuzix completed the second and third tranches of Quanta's investment, totaling $20 million, which validates its waveguide roadmap and manufacturing capabilities [14] - The company ended 2025 with a cash position of $21.2 million and no current or long-term debt, indicating improved financial health [26][27] Q&A Session Summary Question: Expectations for 2026 revenue and significant sources - Management expects OEM and waveguide business revenues to climb throughout 2026, potentially surpassing enterprise branded revenues [33] Question: Anticipation of additional orders and announcements in 2026 - Management indicated that multiple announcements regarding orders and partnerships are expected throughout 2026, contributing to new business opportunities [35]